Lurasidon (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lurasidon" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

61nih.gov

4^th place

13^th place

45web.archive.org

1^st place

42doi.org

2^nd place

4^th place

15semanticscholar.org

11^th place

330^th place

7fda.gov

447^th place

792^nd place

5archive.org

6^th place

2^nd place

4drugs.com

399^th place

480^th place

4europa.eu

68^th place

182^nd place

3books.google.com

3^rd place

6^th place

2latuda.com

low place

2tga.gov.au

3,984^th place

4,575^th place

1medicines.org.uk

3,823^rd place

9,839^th place

1in.gov.br

3,151^st place

low place

1sps.nhs.uk

low place

1wsj.com

79^th place

211^th place

1mmm-online.com

low place

1excli.de

low place

1medscape.com

719^th place

1,112^th place

1jiho.jp

low place

1sumitomo-pharma.com

low place

1rad-ar.or.jp

low place

1medlineplus.gov

1,581^st place

2,421^st place

1wayne.edu

8,028^th place

low place

1worldcat.org

5^th place

7^th place

1ds-pharma.com

low place

1psychotherapeuticdrugs.com

low place

1unc.edu

1,538^th place

1,848^th place

1mdedge.com

low place

1kcl.ac.uk

3,833^rd place

low place

1handle.net

102^nd place

411^th place

1scottishmedicines.org.uk

low place

1hc-sc.gc.ca

low place

4,221^st place

1takeda.com

low place

archive.org (Global: 6^th place; Indonesian: 2^nd place)

Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, et al. (EMBOLDEN I (Trial 001) Investigators) (February 2010). "A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)". The Journal of Clinical Psychiatry. 71 (2): 150–162. doi:10.4088/JCP.08m04995gre. PMID 20122369.
ACOG Committee on Practice Bulletins--Obstetrics (April 2008). "ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation". Obstetrics and Gynecology. 111 (4): 1001–1020. doi:10.1097/AOG.0b013e31816fd910. PMID 18378767.
Herrmann N, Mamdani M, Lanctôt KL (June 2004). "Atypical antipsychotics and risk of cerebrovascular accidents". The American Journal of Psychiatry. 161 (6): 1113–1115. doi:10.1176/appi.ajp.161.6.1113. PMID 15169702.
BMJ Joint Formulary Committee (March 2009). "4.2.1". British National Formulary (Edisi 57). United Kingdom: Royal Pharmaceutical Society of Great Britain. hlm. 192. ISBN 978-0-85369-845-6. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (July 2010). "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity". The Journal of Pharmacology and Experimental Therapeutics. 334 (1): 171–181. doi:10.1124/jpet.110.167346. PMID 20404009. S2CID 12893717.

books.google.com (Global: 3^rd place; Indonesian: 6^th place)

Vardanyan R, Hruby V (7 January 2016). Synthesis of Best-Seller Drugs. Academic Press. ISBN 978-0-12-411524-8. Diarsipkan dari versi aslinya tanggal 11 April 2023. Diakses tanggal 4 September 2017 – via Google Books.
Haddad PM, Dursun S, Deakin B, ed. (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. OUP Oxford. hlm. 207–216. ISBN 978-0-19-852748-0. Diarsipkan dari versi aslinya tanggal 10 January 2023. Diakses tanggal 8 May 2020.
Sacchetti E, Vita A, Siracusano A, Fleischhacker W (2013). Adherence to Antipsychotics in Schizophrenia. Springer Science & Business Media. hlm. 85. ISBN 978-88-470-2679-7. Diarsipkan dari versi aslinya tanggal 10 January 2023. Diakses tanggal 8 May 2020.

doi.org (Global: 2^nd place; Indonesian: 4^th place)

Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C (November 2017). "The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis". BMC Psychiatry. 17 (1): 373. doi:10.1186/s12888-017-1539-0. PMC 5698995. PMID 29162032.
Hanyu S, Kojima Y, Murai T, Kawashima H (September 2022). "Lurasidone-induced hyperosmolar hyperglycemic syndrome: A case report". Neuropsychopharmacology Reports. 42 (3): 377–379. doi:10.1002/npr2.12259. PMC 9515717. PMID 35609885.
Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A (December 2017). "Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment". International Journal of Bipolar Disorders. 5 (1): 9. doi:10.1186/s40345-017-0075-7. PMC 5332323. PMID 28168632.
Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A (April 2017). "Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis". CNS Spectrums. 22 (2): 228–235. doi:10.1017/S1092852917000232. PMID 28300012. S2CID 24653390.
Ali Z, Tegin C, El-Mallakh RS (February 2020). "Evaluating lurasidone as a treatment option for bipolar disorder". Expert Opinion on Pharmacotherapy. 21 (3): 253–260. doi:10.1080/14656566.2019.1695777. PMID 31957501. S2CID 210829608.
Okubo R, Hasegawa T, Fukuyama K, Shiroyama T, Okada M (2021). "Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy". Frontiers in Psychiatry. 12: 623684. doi:10.3389/fpsyt.2021.623684. PMC 7930824. PMID 33679481.
Ragguett RM, McIntyre RS (April 2019). "Cariprazine for the treatment of bipolar depression: a review". Expert Review of Neurotherapeutics. 19 (4): 317–323. doi:10.1080/14737175.2019.1580571. PMID 30753085.
Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, et al. (EMBOLDEN I (Trial 001) Investigators) (February 2010). "A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)". The Journal of Clinical Psychiatry. 71 (2): 150–162. doi:10.4088/JCP.08m04995gre. PMID 20122369.
Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D (February 2010). "Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression". Journal of Affective Disorders. 121 (1–2): 106–115. doi:10.1016/j.jad.2009.10.007. PMID 19903574.
"Corrigendum". Bipolar Disorders. 10 (3): 451. 2008. doi:10.1111/j.1399-5618.2008.00585.x.
Thase ME (February 2008). "Quetiapine monotherapy for bipolar depression". Neuropsychiatric Disease and Treatment. 4 (1): 11–21. doi:10.2147/ndt.s1162. PMC 2515925. PMID 18728771.
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A (November 2003). "Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression". Archives of General Psychiatry. 60 (11): 1079–1088. doi:10.1001/archpsyc.60.11.1079. PMID 14609883.
Tohen M, Katagiri H, Fujikoshi S, Kanba S (July 2013). "Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies". Journal of Affective Disorders. 149 (1–3): 196–201. doi:10.1016/j.jad.2013.01.022. PMID 23485111.
Corya SA, Perlis RH, Keck PE, Lin DY, Case MG, Williamson DJ, Tohen MF (May 2006). "A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression". The Journal of Clinical Psychiatry. 67 (5): 798–806. doi:10.4088/JCP.v67n0514. PMID 16841630.
Azorin JM, Sapin C, Weiller E (February 2013). "Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses". Journal of Affective Disorders. 145 (1): 62–69. doi:10.1016/j.jad.2012.07.013. PMID 22868059.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". Lancet. 378 (9799): 1306–1315. doi:10.1016/S0140-6736(11)60873-8. PMID 21851976. S2CID 25512763.
Tohen M, Ng-Mak D, Rajagopalan K, Halpern R, Chuang CC, Loebel A (June 2017). "Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States". The Primary Care Companion for CNS Disorders. 19 (3). doi:10.4088/PCC.16m02066. PMID 28590601.
Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A (2014). "Lurasidone drug-drug interaction studies: a comprehensive review". Drug Metabolism and Drug Interactions. 29 (3): 191–202. doi:10.1515/dmdi-2014-0005. PMID 24825095.
ACOG Committee on Practice Bulletins--Obstetrics (April 2008). "ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation". Obstetrics and Gynecology. 111 (4): 1001–1020. doi:10.1097/AOG.0b013e31816fd910. PMID 18378767.
Oral H (14 September 2018). "Lurasidone is not associated with risk of QTc prolongation". Clinical Research in Practice: The Journal of Team Hippocrates. 4 (2). doi:10.22237/crp/1536278400. ISSN 2379-4550. S2CID 53322344. Diarsipkan dari versi aslinya tanggal 15 November 2022. Diakses tanggal 15 November 2022.
Javed A, Arthur H, Curtis L, Hansen L, Pappa S (December 2019). "Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia". Neurology and Therapy. 8 (2): 215–230. doi:10.1007/s40120-019-0138-z. PMC 6858892. PMID 31098889.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
Herrmann N, Mamdani M, Lanctôt KL (June 2004). "Atypical antipsychotics and risk of cerebrovascular accidents". The American Journal of Psychiatry. 161 (6): 1113–1115. doi:10.1176/appi.ajp.161.6.1113. PMID 15169702.
Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A (November 2015). "Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia". International Clinical Psychopharmacology. 30 (6): 342–350. doi:10.1097/YIC.0000000000000091. PMC 4593468. PMID 26196189.
Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A (May 2016). "Lurasidone in the Long-Term Treatment of Patients with Bipolar Disorder: A 24-Week Open-Label Extension Study". Depression and Anxiety. 33 (5): 424–434. doi:10.1002/da.22479. PMC 5069590. PMID 26918425.
Zheng W, Cai DB, Yang XH, Li L, Zhang QE, Ng CH, Ungvari GS, Li XB, Ning YP, Xiang YT (August 2018). "Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials". Journal of Psychiatric Research. 103: 244–251. doi:10.1016/j.jpsychires.2018.06.005. PMID 29906709. S2CID 49227958.
Kolli V, Walia A, Kinnan S (March 2019). "Food Matters: Reduction of Lurasidone-Induced Nausea With Meals". The Primary Care Companion for CNS Disorders. 21 (2): 18l02343. doi:10.4088/PCC.18l02343. PMID 30869204. S2CID 76666344.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. S2CID 6267180.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (July 2010). "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity". The Journal of Pharmacology and Experimental Therapeutics. 334 (1): 171–181. doi:10.1124/jpet.110.167346. PMID 20404009. S2CID 12893717.
Wróbel MZ, Chodkowski A, Herold F, Marciniak M, Dawidowski M, Siwek A, Starowicz G, Stachowicz K, Szewczyk B, Nowak G, Belka M, Bączek T, Satała G, Bojarski AJ, Turło J (December 2019). "Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect". European Journal of Medicinal Chemistry. 183: 111736. doi:10.1016/j.ejmech.2019.111736. PMID 31586817.
Bender AM, Parr LC, Livingston WB, Lindsley CW, Merryman WD (August 2023). "2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery". J Med Chem. 66 (16): 11027–11039. doi:10.1021/acs.jmedchem.3c01178. PMC 11073569. PMID 37584406.
Tarazi FI, Riva MA (October 2013). "The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia". Expert Opinion on Drug Discovery. 8 (10): 1297–1307. doi:10.1517/17460441.2013.815163. PMID 23837554. S2CID 25838798.
Amerio A, Giacomini C, Fusar-Poli L, Aguglia A, Costanza A, Serafini G, Aguglia E, Amore M (2021). "Efficacy and Safety of Lurasidone in Children and Adolescents: Recommendations for Clinical Management and Future Research". Current Pharmaceutical Design. 27 (39): 4062–4069. doi:10.2174/1381612827666210804110853. PMID 34348620. S2CID 236926992.
Fountoulakis KN, Gazouli M, Kelsoe J, Akiskal H (March 2015). "The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder". European Neuropsychopharmacology. 25 (3): 335–342. doi:10.1016/j.euroneuro.2014.11.010. PMID 25596883. S2CID 25628197.
Franklin R, Zorowitz S, Corse AK, Widge AS, Deckersbach T (19 August 2015). "Lurasidone for the treatment of bipolar depression: an evidence-based review". Neuropsychiatric Disease and Treatment. 11: 2143–2152. doi:10.2147/NDT.S50961. PMC 4547662. PMID 26316760.
Samalin L, Ben Gharbia M, Garnier M, Llorca PM (December 2014). "[Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]" [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale (dalam bahasa Prancis). 40 (6): 507–517. doi:10.1016/j.encep.2014.10.009. PMID 25453735.
Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y (October 2007). "Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test". European Journal of Pharmacology. 572 (2–3): 160–170. doi:10.1016/j.ejphar.2007.06.058. PMID 17662268.
Greenberg WM, Citrome L (May 2017). "Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature". Clinical Pharmacokinetics. 56 (5): 493–503. doi:10.1007/s40262-016-0465-5. PMID 27722855. S2CID 207485482.
Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A (September 2019). "Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone". European Neuropsychopharmacology. 29 (9): 971–985. doi:10.1016/j.euroneuro.2019.06.008. hdl:11585/714012. PMID 31255396. S2CID 195699303.
Wong DF, Kuwabara H, Brašić JR, Stock T, Maini A, Gean EG, Loebel A (September 2013). "Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects". Psychopharmacology. 229 (2): 245–252. doi:10.1007/s00213-013-3103-z. PMID 23649882. S2CID 253737308.
Katteboina MY, Pilli NR, Mullangi R, Seelam RR, Satla SR (July 2016). "LC-MS/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study". Biomedical Chromatography. 30 (7): 1065–1074. doi:10.1002/bmc.3651. PMID 26577488.
Caccia S, Pasina L, Nobili A (2012). "Critical appraisal of lurasidone in the management of schizophrenia". Neuropsychiatric Disease and Treatment. 8: 155–168. doi:10.2147/NDT.S18059. PMC 3346058. PMID 22570547.

drugs.com (Global: 399^th place; Indonesian: 480^th place)

"Lurasidone (Latuda) Use During Pregnancy". Drugs.com. 5 February 2020. Diarsipkan dari versi aslinya tanggal 15 October 2020. Diakses tanggal 12 May 2020.
"Lurasidone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Diarsipkan dari versi aslinya tanggal 21 March 2019. Diakses tanggal 21 March 2019.
"Generic Latuda Availability". Drugs.com. Diarsipkan dari versi aslinya tanggal 14 August 2020. Diakses tanggal 30 April 2020.
"Latuda". Drugs.com. Diarsipkan dari versi aslinya tanggal 5 April 2019. Diakses tanggal 17 December 2010.

ds-pharma.com (Global: low place; Indonesian: low place)

"Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study" (Press release). Dainippon Sumitomo Pharma. 26 August 2009. Diarsipkan dari asli tanggal 14 May 2015. Diakses tanggal 3 October 2016.

europa.eu (Global: 68^th place; Indonesian: 182^nd place)

ema.europa.eu

"Latuda EPAR". European Medicines Agency (EMA). 17 September 2018. Diarsipkan dari versi aslinya tanggal 11 August 2020. Diakses tanggal 12 May 2020. Artikel ini memuat teks dari sumber tersebut, yang berada dalam ranah publik.
"Latuda: EPAR – Product Information" (PDF). European Medicines Agency. 14 April 2016. Diarsipkan (PDF) dari versi aslinya tanggal 21 August 2016. Diakses tanggal 27 February 2017.
"Latuda (lurasidone) An overview. European Medicines Agency, 2020" (PDF). Diarsipkan (PDF) dari versi aslinya tanggal 6 October 2022. Diakses tanggal 6 October 2022.
"European Medicines Agency Assessment report Latuda International non-proprietary name: LURASIDONE Procedure No. EMEA/H/C/002713/0000" (PDF). Diarsipkan (PDF) dari versi aslinya tanggal 14 November 2022. Diakses tanggal 14 November 2022.

excli.de (Global: low place; Indonesian: low place)

"EXCLI Journal" (PDF). 17 November 2016. Diarsipkan dari asli (PDF) tanggal 17 November 2016.

fda.gov (Global: 447^th place; Indonesian: 792^nd place)

accessdata.fda.gov

"Latuda Supplement Approval Package 1" (PDF). U.S. Food and Drug Administration (FDA). Diarsipkan dari asli (PDF) tanggal 27 July 2020. Diakses tanggal 12 May 2020.
"Latuda Supplement Approval Package 2" (PDF). U.S. Food and Drug Administration (FDA). Diarsipkan (PDF) dari versi aslinya tanggal 28 August 2021. Diakses tanggal 12 May 2020.
"Lurasidone pharmacology review" (PDF). Center for Drug Evaluation and Research. 30 December 2009. Diarsipkan dari asli (PDF) tanggal 3 October 2016. Diakses tanggal 2 October 2016.
"Drug Approval Package: Latuda (lurasidone hydrochloride) Tablets NDA #200603". U.S. Food and Drug Administration (FDA). 24 December 1999. Diarsipkan dari asli tanggal 25 February 2021. Diakses tanggal 12 May 2020.
"Lurasidone: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Diarsipkan dari asli tanggal 1 October 2020. Diakses tanggal 12 May 2020.

fda.gov

Office of the Commissioner (14 July 2021). "Grapefruit Juice and Some Drugs Don't Mix". FDA (dalam bahasa Inggris). Diarsipkan dari asli tanggal 6 May 2019.
"FDA approves Latuda to treat schizophrenia in adults" (Press release). U.S. Food and Drug Administration (FDA). 28 October 2010. Diarsipkan dari asli tanggal 30 October 2010. Diakses tanggal 29 October 2010.

handle.net (Global: 102^nd place; Indonesian: 411^th place)

hdl.handle.net

Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A (September 2019). "Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone". European Neuropsychopharmacology. 29 (9): 971–985. doi:10.1016/j.euroneuro.2019.06.008. hdl:11585/714012. PMID 31255396. S2CID 195699303.

hc-sc.gc.ca (Global: low place; Indonesian: 4,221^st place)

"Summary Basis of Decision (SBD) for Latuda". hc-sc.gc.ca. Health Canada. 2012. Diarsipkan dari versi aslinya tanggal 27 June 2013. Diakses tanggal 19 June 2013.

in.gov.br (Global: 3,151^st place; Indonesian: low place)

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (dalam bahasa Brazilian Portuguese). Diário Oficial da União (dipublikasikan 4 April 2023). Diarsipkan dari versi aslinya tanggal 3 August 2023. Diakses tanggal 16 August 2023.

jiho.jp (Global: low place; Indonesian: low place)

pj.jiho.jp

"Latuda to Finally Hit Japan Market on June 11". PHARMA JAPAN (dalam bahasa Inggris). Diarsipkan dari versi aslinya tanggal 10 October 2022. Diakses tanggal 10 October 2022.

kcl.ac.uk (Global: 3,833^rd place; Indonesian: low place)

kclpure.kcl.ac.uk

Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A (September 2019). "Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone". European Neuropsychopharmacology. 29 (9): 971–985. doi:10.1016/j.euroneuro.2019.06.008. hdl:11585/714012. PMID 31255396. S2CID 195699303.

latuda.com (Global: low place; Indonesian: low place)

"IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA". Latuda. Diarsipkan dari versi aslinya tanggal 3 December 2022. Diakses tanggal 3 December 2022.
"Latuda Prescribing Information" (PDF). Sunovion Pharmaceuticals. Diarsipkan (PDF) dari versi aslinya tanggal 12 July 2018. Diakses tanggal 25 March 2014.

mdedge.com (Global: low place; Indonesian: low place)

Lincoln J, Tripathi A (2011). "Lurasidone for Schizophrenia". Current Psychiatry. 10 (1): 67–70. Diarsipkan dari versi aslinya tanggal 3 October 2016. Diakses tanggal 2 October 2016.

medicines.org.uk (Global: 3,823^rd place; Indonesian: 9,839^th place)

"Latuda 18.5mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2019. Diarsipkan dari versi aslinya tanggal 14 October 2020. Diakses tanggal 12 May 2020.

medlineplus.gov (Global: 1,581^st place; Indonesian: 2,421^st place)

"Lurasidone". MedlinePlus. U.S. National Library of Medicine. Diarsipkan dari versi aslinya tanggal 23 January 2019. Diakses tanggal 11 September 2018.

medscape.com (Global: 719^th place; Indonesian: 1,112^th place)

Lowes R (2013). "Lurasidone Approved for Bipolar Depression". Medscape. Diarsipkan dari versi aslinya tanggal 2 October 2013. Diakses tanggal 1 October 2013.

mmm-online.com (Global: low place; Indonesian: low place)

"Leading Latuda through the crowd". 1 October 2011. Diarsipkan dari versi aslinya tanggal 28 August 2018. Diakses tanggal 25 June 2017. Latuda was developed at an R&D facility established in Fort Lee, NJ, about eight years ago by Sunovion's Japanese parent Dainippon Sumitomo Pharma Co. (DSP).

nih.gov (Global: 4^th place; Indonesian: 13^th place)

pubmed.ncbi.nlm.nih.gov

Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C (November 2017). "The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis". BMC Psychiatry. 17 (1): 373. doi:10.1186/s12888-017-1539-0. PMC 5698995. PMID 29162032.
Hanyu S, Kojima Y, Murai T, Kawashima H (September 2022). "Lurasidone-induced hyperosmolar hyperglycemic syndrome: A case report". Neuropsychopharmacology Reports. 42 (3): 377–379. doi:10.1002/npr2.12259. PMC 9515717. PMID 35609885.
Bawa R, Scarff JR (2015). "Lurasidone: a new treatment option for bipolar depression-a review". Innovations in Clinical Neuroscience. 12 (1–2): 21–23. PMC 4382136. PMID 25852975.
Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A (December 2017). "Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment". International Journal of Bipolar Disorders. 5 (1): 9. doi:10.1186/s40345-017-0075-7. PMC 5332323. PMID 28168632.
Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A (April 2017). "Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis". CNS Spectrums. 22 (2): 228–235. doi:10.1017/S1092852917000232. PMID 28300012. S2CID 24653390.
Ali Z, Tegin C, El-Mallakh RS (February 2020). "Evaluating lurasidone as a treatment option for bipolar disorder". Expert Opinion on Pharmacotherapy. 21 (3): 253–260. doi:10.1080/14656566.2019.1695777. PMID 31957501. S2CID 210829608.
Okubo R, Hasegawa T, Fukuyama K, Shiroyama T, Okada M (2021). "Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy". Frontiers in Psychiatry. 12: 623684. doi:10.3389/fpsyt.2021.623684. PMC 7930824. PMID 33679481.
Ragguett RM, McIntyre RS (April 2019). "Cariprazine for the treatment of bipolar depression: a review". Expert Review of Neurotherapeutics. 19 (4): 317–323. doi:10.1080/14737175.2019.1580571. PMID 30753085.
Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, et al. (EMBOLDEN I (Trial 001) Investigators) (February 2010). "A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)". The Journal of Clinical Psychiatry. 71 (2): 150–162. doi:10.4088/JCP.08m04995gre. PMID 20122369.
Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D (February 2010). "Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression". Journal of Affective Disorders. 121 (1–2): 106–115. doi:10.1016/j.jad.2009.10.007. PMID 19903574.
Thase ME (February 2008). "Quetiapine monotherapy for bipolar depression". Neuropsychiatric Disease and Treatment. 4 (1): 11–21. doi:10.2147/ndt.s1162. PMC 2515925. PMID 18728771.
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A (November 2003). "Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression". Archives of General Psychiatry. 60 (11): 1079–1088. doi:10.1001/archpsyc.60.11.1079. PMID 14609883.
Tohen M, Katagiri H, Fujikoshi S, Kanba S (July 2013). "Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies". Journal of Affective Disorders. 149 (1–3): 196–201. doi:10.1016/j.jad.2013.01.022. PMID 23485111.
Corya SA, Perlis RH, Keck PE, Lin DY, Case MG, Williamson DJ, Tohen MF (May 2006). "A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression". The Journal of Clinical Psychiatry. 67 (5): 798–806. doi:10.4088/JCP.v67n0514. PMID 16841630.
Azorin JM, Sapin C, Weiller E (February 2013). "Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses". Journal of Affective Disorders. 145 (1): 62–69. doi:10.1016/j.jad.2012.07.013. PMID 22868059.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". Lancet. 378 (9799): 1306–1315. doi:10.1016/S0140-6736(11)60873-8. PMID 21851976. S2CID 25512763.
Tohen M, Ng-Mak D, Rajagopalan K, Halpern R, Chuang CC, Loebel A (June 2017). "Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States". The Primary Care Companion for CNS Disorders. 19 (3). doi:10.4088/PCC.16m02066. PMID 28590601.
Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A (2014). "Lurasidone drug-drug interaction studies: a comprehensive review". Drug Metabolism and Drug Interactions. 29 (3): 191–202. doi:10.1515/dmdi-2014-0005. PMID 24825095.
ACOG Committee on Practice Bulletins--Obstetrics (April 2008). "ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation". Obstetrics and Gynecology. 111 (4): 1001–1020. doi:10.1097/AOG.0b013e31816fd910. PMID 18378767.
Javed A, Arthur H, Curtis L, Hansen L, Pappa S (December 2019). "Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia". Neurology and Therapy. 8 (2): 215–230. doi:10.1007/s40120-019-0138-z. PMC 6858892. PMID 31098889.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
Herrmann N, Mamdani M, Lanctôt KL (June 2004). "Atypical antipsychotics and risk of cerebrovascular accidents". The American Journal of Psychiatry. 161 (6): 1113–1115. doi:10.1176/appi.ajp.161.6.1113. PMID 15169702.
Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A (November 2015). "Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia". International Clinical Psychopharmacology. 30 (6): 342–350. doi:10.1097/YIC.0000000000000091. PMC 4593468. PMID 26196189.
Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A (May 2016). "Lurasidone in the Long-Term Treatment of Patients with Bipolar Disorder: A 24-Week Open-Label Extension Study". Depression and Anxiety. 33 (5): 424–434. doi:10.1002/da.22479. PMC 5069590. PMID 26918425.
Zheng W, Cai DB, Yang XH, Li L, Zhang QE, Ng CH, Ungvari GS, Li XB, Ning YP, Xiang YT (August 2018). "Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials". Journal of Psychiatric Research. 103: 244–251. doi:10.1016/j.jpsychires.2018.06.005. PMID 29906709. S2CID 49227958.
Kolli V, Walia A, Kinnan S (March 2019). "Food Matters: Reduction of Lurasidone-Induced Nausea With Meals". The Primary Care Companion for CNS Disorders. 21 (2): 18l02343. doi:10.4088/PCC.18l02343. PMID 30869204. S2CID 76666344.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. S2CID 6267180.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (July 2010). "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity". The Journal of Pharmacology and Experimental Therapeutics. 334 (1): 171–181. doi:10.1124/jpet.110.167346. PMID 20404009. S2CID 12893717.
Wróbel MZ, Chodkowski A, Herold F, Marciniak M, Dawidowski M, Siwek A, Starowicz G, Stachowicz K, Szewczyk B, Nowak G, Belka M, Bączek T, Satała G, Bojarski AJ, Turło J (December 2019). "Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect". European Journal of Medicinal Chemistry. 183: 111736. doi:10.1016/j.ejmech.2019.111736. PMID 31586817.
Bender AM, Parr LC, Livingston WB, Lindsley CW, Merryman WD (August 2023). "2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery". J Med Chem. 66 (16): 11027–11039. doi:10.1021/acs.jmedchem.3c01178. PMC 11073569. PMID 37584406.
Tarazi FI, Riva MA (October 2013). "The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia". Expert Opinion on Drug Discovery. 8 (10): 1297–1307. doi:10.1517/17460441.2013.815163. PMID 23837554. S2CID 25838798.
Amerio A, Giacomini C, Fusar-Poli L, Aguglia A, Costanza A, Serafini G, Aguglia E, Amore M (2021). "Efficacy and Safety of Lurasidone in Children and Adolescents: Recommendations for Clinical Management and Future Research". Current Pharmaceutical Design. 27 (39): 4062–4069. doi:10.2174/1381612827666210804110853. PMID 34348620. S2CID 236926992.
Fountoulakis KN, Gazouli M, Kelsoe J, Akiskal H (March 2015). "The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder". European Neuropsychopharmacology. 25 (3): 335–342. doi:10.1016/j.euroneuro.2014.11.010. PMID 25596883. S2CID 25628197.
Franklin R, Zorowitz S, Corse AK, Widge AS, Deckersbach T (19 August 2015). "Lurasidone for the treatment of bipolar depression: an evidence-based review". Neuropsychiatric Disease and Treatment. 11: 2143–2152. doi:10.2147/NDT.S50961. PMC 4547662. PMID 26316760.
Samalin L, Ben Gharbia M, Garnier M, Llorca PM (December 2014). "[Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]" [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale (dalam bahasa Prancis). 40 (6): 507–517. doi:10.1016/j.encep.2014.10.009. PMID 25453735.
Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y (October 2007). "Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test". European Journal of Pharmacology. 572 (2–3): 160–170. doi:10.1016/j.ejphar.2007.06.058. PMID 17662268.
Greenberg WM, Citrome L (May 2017). "Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature". Clinical Pharmacokinetics. 56 (5): 493–503. doi:10.1007/s40262-016-0465-5. PMID 27722855. S2CID 207485482.
Cruz MP (August 2011). "Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia". P & T. 36 (8): 489–492. PMC 3171824. PMID 21935296.
Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A (September 2019). "Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone". European Neuropsychopharmacology. 29 (9): 971–985. doi:10.1016/j.euroneuro.2019.06.008. hdl:11585/714012. PMID 31255396. S2CID 195699303.
Wong DF, Kuwabara H, Brašić JR, Stock T, Maini A, Gean EG, Loebel A (September 2013). "Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects". Psychopharmacology. 229 (2): 245–252. doi:10.1007/s00213-013-3103-z. PMID 23649882. S2CID 253737308.
Katteboina MY, Pilli NR, Mullangi R, Seelam RR, Satla SR (July 2016). "LC-MS/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study". Biomedical Chromatography. 30 (7): 1065–1074. doi:10.1002/bmc.3651. PMID 26577488.
Caccia S, Pasina L, Nobili A (2012). "Critical appraisal of lurasidone in the management of schizophrenia". Neuropsychiatric Disease and Treatment. 8: 155–168. doi:10.2147/NDT.S18059. PMC 3346058. PMID 22570547.
Carey H, Fondriest M (June 2017). "Cost-Savings From an Antipsychotic Tablet-Splitting Program". P & T. 42 (6): 384–393. PMC 5440099. PMID 28579725.

ncbi.nlm.nih.gov

Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C (November 2017). "The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis". BMC Psychiatry. 17 (1): 373. doi:10.1186/s12888-017-1539-0. PMC 5698995. PMID 29162032.
Hanyu S, Kojima Y, Murai T, Kawashima H (September 2022). "Lurasidone-induced hyperosmolar hyperglycemic syndrome: A case report". Neuropsychopharmacology Reports. 42 (3): 377–379. doi:10.1002/npr2.12259. PMC 9515717. PMID 35609885.
Bawa R, Scarff JR (2015). "Lurasidone: a new treatment option for bipolar depression-a review". Innovations in Clinical Neuroscience. 12 (1–2): 21–23. PMC 4382136. PMID 25852975.
Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A (December 2017). "Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment". International Journal of Bipolar Disorders. 5 (1): 9. doi:10.1186/s40345-017-0075-7. PMC 5332323. PMID 28168632.
Canadian Agency for Drugs and Technologies in Health (2014). "Key Limitations". Lurasidone Hydrochloride (Latuda): Management of Manifestations of Schizophrenia. Canadian Agency for Drugs and Technologies in Health. Diarsipkan dari versi aslinya tanggal 28 August 2021. Diakses tanggal 30 April 2020 – via National Center for Biotechnology Information, U.S. National Library of Medicine.
Okubo R, Hasegawa T, Fukuyama K, Shiroyama T, Okada M (2021). "Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy". Frontiers in Psychiatry. 12: 623684. doi:10.3389/fpsyt.2021.623684. PMC 7930824. PMID 33679481.
Thase ME (February 2008). "Quetiapine monotherapy for bipolar depression". Neuropsychiatric Disease and Treatment. 4 (1): 11–21. doi:10.2147/ndt.s1162. PMC 2515925. PMID 18728771.
Javed A, Arthur H, Curtis L, Hansen L, Pappa S (December 2019). "Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia". Neurology and Therapy. 8 (2): 215–230. doi:10.1007/s40120-019-0138-z. PMC 6858892. PMID 31098889.
Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A (November 2015). "Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia". International Clinical Psychopharmacology. 30 (6): 342–350. doi:10.1097/YIC.0000000000000091. PMC 4593468. PMID 26196189.
Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A (May 2016). "Lurasidone in the Long-Term Treatment of Patients with Bipolar Disorder: A 24-Week Open-Label Extension Study". Depression and Anxiety. 33 (5): 424–434. doi:10.1002/da.22479. PMC 5069590. PMID 26918425.
Bender AM, Parr LC, Livingston WB, Lindsley CW, Merryman WD (August 2023). "2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery". J Med Chem. 66 (16): 11027–11039. doi:10.1021/acs.jmedchem.3c01178. PMC 11073569. PMID 37584406.
Franklin R, Zorowitz S, Corse AK, Widge AS, Deckersbach T (19 August 2015). "Lurasidone for the treatment of bipolar depression: an evidence-based review". Neuropsychiatric Disease and Treatment. 11: 2143–2152. doi:10.2147/NDT.S50961. PMC 4547662. PMID 26316760.
Cruz MP (August 2011). "Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia". P & T. 36 (8): 489–492. PMC 3171824. PMID 21935296.
Caccia S, Pasina L, Nobili A (2012). "Critical appraisal of lurasidone in the management of schizophrenia". Neuropsychiatric Disease and Treatment. 8: 155–168. doi:10.2147/NDT.S18059. PMC 3346058. PMID 22570547.
Canadian Agency for Drugs and Technologies in Health (2014). "Summary of Pharmacoeconomic Submission". Lurasidone Hydrochloride (Latuda): Management of Manifestations of Schizophrenia. Canadian Agency for Drugs and Technologies in Health. Diarsipkan dari versi aslinya tanggal 28 August 2021. Diakses tanggal 30 April 2020 – via National Center for Biotechnology Information, U.S. National Library of Medicine.
Carey H, Fondriest M (June 2017). "Cost-Savings From an Antipsychotic Tablet-Splitting Program". P & T. 42 (6): 384–393. PMC 5440099. PMID 28579725.

dailymed.nlm.nih.gov

"Latuda- lurasidone hydrochloride tablet, film coated". DailyMed. Diarsipkan dari versi aslinya tanggal 28 August 2021. Diakses tanggal 12 May 2020.

pubchem.ncbi.nlm.nih.gov

"(3aR,4S,7R,7aS)-2-[[(1R,2R)-2-[[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione". PubChem (dalam bahasa Inggris). U.S. National Library of Medicine. Diarsipkan dari versi aslinya tanggal 2 December 2022. Diakses tanggal 2 December 2022.

psychotherapeuticdrugs.com (Global: low place; Indonesian: low place)

"Latuda: Prescribing Information". Psychotherapeutic Drugs. Diarsipkan dari asli tanggal 28 June 2011. Diakses tanggal 17 December 2010.

rad-ar.or.jp (Global: low place; Indonesian: low place)

"Kusuri-no-Shiori(Drug Information Sheet) Latuda tablets" (dalam bahasa Inggris). Diarsipkan dari versi aslinya tanggal 10 October 2022. Diakses tanggal 10 October 2022.

scottishmedicines.org.uk (Global: low place; Indonesian: low place)

"Lurasidone, 18.5mg, 37mg, 74mg film-coated tablets (Latuda) SMC No. (994/14)" (PDF). scottishmedicines.org.uk. Scottish Medicines Consortium. 2014. Diarsipkan dari asli (PDF) tanggal 8 March 2016. Diakses tanggal 7 March 2016.

semanticscholar.org (Global: 11^th place; Indonesian: 330^th place)

api.semanticscholar.org

Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A (April 2017). "Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis". CNS Spectrums. 22 (2): 228–235. doi:10.1017/S1092852917000232. PMID 28300012. S2CID 24653390.
Ali Z, Tegin C, El-Mallakh RS (February 2020). "Evaluating lurasidone as a treatment option for bipolar disorder". Expert Opinion on Pharmacotherapy. 21 (3): 253–260. doi:10.1080/14656566.2019.1695777. PMID 31957501. S2CID 210829608.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". Lancet. 378 (9799): 1306–1315. doi:10.1016/S0140-6736(11)60873-8. PMID 21851976. S2CID 25512763.
Oral H (14 September 2018). "Lurasidone is not associated with risk of QTc prolongation". Clinical Research in Practice: The Journal of Team Hippocrates. 4 (2). doi:10.22237/crp/1536278400. ISSN 2379-4550. S2CID 53322344. Diarsipkan dari versi aslinya tanggal 15 November 2022. Diakses tanggal 15 November 2022.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
Zheng W, Cai DB, Yang XH, Li L, Zhang QE, Ng CH, Ungvari GS, Li XB, Ning YP, Xiang YT (August 2018). "Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials". Journal of Psychiatric Research. 103: 244–251. doi:10.1016/j.jpsychires.2018.06.005. PMID 29906709. S2CID 49227958.
Kolli V, Walia A, Kinnan S (March 2019). "Food Matters: Reduction of Lurasidone-Induced Nausea With Meals". The Primary Care Companion for CNS Disorders. 21 (2): 18l02343. doi:10.4088/PCC.18l02343. PMID 30869204. S2CID 76666344.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. S2CID 6267180.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (July 2010). "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity". The Journal of Pharmacology and Experimental Therapeutics. 334 (1): 171–181. doi:10.1124/jpet.110.167346. PMID 20404009. S2CID 12893717.
Tarazi FI, Riva MA (October 2013). "The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia". Expert Opinion on Drug Discovery. 8 (10): 1297–1307. doi:10.1517/17460441.2013.815163. PMID 23837554. S2CID 25838798.
Amerio A, Giacomini C, Fusar-Poli L, Aguglia A, Costanza A, Serafini G, Aguglia E, Amore M (2021). "Efficacy and Safety of Lurasidone in Children and Adolescents: Recommendations for Clinical Management and Future Research". Current Pharmaceutical Design. 27 (39): 4062–4069. doi:10.2174/1381612827666210804110853. PMID 34348620. S2CID 236926992.
Fountoulakis KN, Gazouli M, Kelsoe J, Akiskal H (March 2015). "The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder". European Neuropsychopharmacology. 25 (3): 335–342. doi:10.1016/j.euroneuro.2014.11.010. PMID 25596883. S2CID 25628197.
Greenberg WM, Citrome L (May 2017). "Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature". Clinical Pharmacokinetics. 56 (5): 493–503. doi:10.1007/s40262-016-0465-5. PMID 27722855. S2CID 207485482.
Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A (September 2019). "Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone". European Neuropsychopharmacology. 29 (9): 971–985. doi:10.1016/j.euroneuro.2019.06.008. hdl:11585/714012. PMID 31255396. S2CID 195699303.
Wong DF, Kuwabara H, Brašić JR, Stock T, Maini A, Gean EG, Loebel A (September 2013). "Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects". Psychopharmacology. 229 (2): 245–252. doi:10.1007/s00213-013-3103-z. PMID 23649882. S2CID 253737308.

sps.nhs.uk (Global: low place; Indonesian: low place)

"Lurasidone (Latuda) tablets for the treatment of schizophrenia in adults" (PDF). Diarsipkan dari asli (PDF) tanggal 27 February 2021. Diakses tanggal 30 April 2020.

sumitomo-pharma.com (Global: low place; Indonesian: low place)

"Sumitomo Dainippon Pharma Announces Approval of Atypical Antipsychotic Agent, LATUDA Tablets in Japan". IR News | Investor Relations (dalam bahasa Inggris). Sumitomo Pharma. Diarsipkan dari versi aslinya tanggal 10 October 2022. Diakses tanggal 10 October 2022.

takeda.com (Global: low place; Indonesian: low place)

tpi.takeda.com

"European Marketing Authorization for Latuda". takeda.com. Diarsipkan dari asli tanggal 26 December 2017. Diakses tanggal 25 November 2015.

tga.gov.au (Global: 3,984^th place; Indonesian: 4,575^th place)

ebs.tga.gov.au

"Product information Latuda (lurasidone hydrochloride)" (PDF). TGA eBusiness Services. Therapeutic Goods Administration. 28 October 2022. Diarsipkan dari versi aslinya tanggal 28 October 2022. Diakses tanggal 28 October 2022.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Diarsipkan dari versi aslinya tanggal 10 April 2023. Diakses tanggal 10 April 2023.

unc.edu (Global: 1,538^th place; Indonesian: 1,848^th place)

pdsp.unc.edu

Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Diarsipkan dari versi aslinya tanggal 28 August 2021. Diakses tanggal 14 August 2017.

wayne.edu (Global: 8,028^th place; Indonesian: low place)

digitalcommons.wayne.edu

Oral H (14 September 2018). "Lurasidone is not associated with risk of QTc prolongation". Clinical Research in Practice: The Journal of Team Hippocrates. 4 (2). doi:10.22237/crp/1536278400. ISSN 2379-4550. S2CID 53322344. Diarsipkan dari versi aslinya tanggal 15 November 2022. Diakses tanggal 15 November 2022.

web.archive.org (Global: 1^st place; Indonesian: 1^st place)

"Lurasidone (Latuda) Use During Pregnancy". Drugs.com. 5 February 2020. Diarsipkan dari versi aslinya tanggal 15 October 2020. Diakses tanggal 12 May 2020.
"Lurasidone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Diarsipkan dari versi aslinya tanggal 21 March 2019. Diakses tanggal 21 March 2019.
"Product information Latuda (lurasidone hydrochloride)" (PDF). TGA eBusiness Services. Therapeutic Goods Administration. 28 October 2022. Diarsipkan dari versi aslinya tanggal 28 October 2022. Diakses tanggal 28 October 2022.
"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Diarsipkan dari versi aslinya tanggal 10 April 2023. Diakses tanggal 10 April 2023.
"Latuda 18.5mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2019. Diarsipkan dari versi aslinya tanggal 14 October 2020. Diakses tanggal 12 May 2020.
"Latuda- lurasidone hydrochloride tablet, film coated". DailyMed. Diarsipkan dari versi aslinya tanggal 28 August 2021. Diakses tanggal 12 May 2020.
"Latuda EPAR". European Medicines Agency (EMA). 17 September 2018. Diarsipkan dari versi aslinya tanggal 11 August 2020. Diakses tanggal 12 May 2020. Artikel ini memuat teks dari sumber tersebut, yang berada dalam ranah publik.
"Latuda: EPAR – Product Information" (PDF). European Medicines Agency. 14 April 2016. Diarsipkan (PDF) dari versi aslinya tanggal 21 August 2016. Diakses tanggal 27 February 2017.
Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (dalam bahasa Brazilian Portuguese). Diário Oficial da União (dipublikasikan 4 April 2023). Diarsipkan dari versi aslinya tanggal 3 August 2023. Diakses tanggal 16 August 2023.
"IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA". Latuda. Diarsipkan dari versi aslinya tanggal 3 December 2022. Diakses tanggal 3 December 2022.
"Lurasidone (Latuda) tablets for the treatment of schizophrenia in adults" (PDF). Diarsipkan dari asli (PDF) tanggal 27 February 2021. Diakses tanggal 30 April 2020.
"Generic Latuda Availability". Drugs.com. Diarsipkan dari versi aslinya tanggal 14 August 2020. Diakses tanggal 30 April 2020.
Hopkins JS (19 November 2019). "Generic-Drug Approvals Soar, But Patients Still Go Without". Wall Street Journal. Diarsipkan dari versi aslinya tanggal 27 April 2020. Diakses tanggal 30 April 2020.
"Leading Latuda through the crowd". 1 October 2011. Diarsipkan dari versi aslinya tanggal 28 August 2018. Diakses tanggal 25 June 2017. Latuda was developed at an R&D facility established in Fort Lee, NJ, about eight years ago by Sunovion's Japanese parent Dainippon Sumitomo Pharma Co. (DSP).
Vardanyan R, Hruby V (7 January 2016). Synthesis of Best-Seller Drugs. Academic Press. ISBN 978-0-12-411524-8. Diarsipkan dari versi aslinya tanggal 11 April 2023. Diakses tanggal 4 September 2017 – via Google Books.
"EXCLI Journal" (PDF). 17 November 2016. Diarsipkan dari asli (PDF) tanggal 17 November 2016.
"Latuda (lurasidone) An overview. European Medicines Agency, 2020" (PDF). Diarsipkan (PDF) dari versi aslinya tanggal 6 October 2022. Diakses tanggal 6 October 2022.
Canadian Agency for Drugs and Technologies in Health (2014). "Key Limitations". Lurasidone Hydrochloride (Latuda): Management of Manifestations of Schizophrenia. Canadian Agency for Drugs and Technologies in Health. Diarsipkan dari versi aslinya tanggal 28 August 2021. Diakses tanggal 30 April 2020 – via National Center for Biotechnology Information, U.S. National Library of Medicine.
Lowes R (2013). "Lurasidone Approved for Bipolar Depression". Medscape. Diarsipkan dari versi aslinya tanggal 2 October 2013. Diakses tanggal 1 October 2013.
"Latuda Supplement Approval Package 1" (PDF). U.S. Food and Drug Administration (FDA). Diarsipkan dari asli (PDF) tanggal 27 July 2020. Diakses tanggal 12 May 2020.
"Latuda Supplement Approval Package 2" (PDF). U.S. Food and Drug Administration (FDA). Diarsipkan (PDF) dari versi aslinya tanggal 28 August 2021. Diakses tanggal 12 May 2020.
"Latuda to Finally Hit Japan Market on June 11". PHARMA JAPAN (dalam bahasa Inggris). Diarsipkan dari versi aslinya tanggal 10 October 2022. Diakses tanggal 10 October 2022.
"Sumitomo Dainippon Pharma Announces Approval of Atypical Antipsychotic Agent, LATUDA Tablets in Japan". IR News | Investor Relations (dalam bahasa Inggris). Sumitomo Pharma. Diarsipkan dari versi aslinya tanggal 10 October 2022. Diakses tanggal 10 October 2022.
"Kusuri-no-Shiori(Drug Information Sheet) Latuda tablets" (dalam bahasa Inggris). Diarsipkan dari versi aslinya tanggal 10 October 2022. Diakses tanggal 10 October 2022.
"Lurasidone". MedlinePlus. U.S. National Library of Medicine. Diarsipkan dari versi aslinya tanggal 23 January 2019. Diakses tanggal 11 September 2018.
Office of the Commissioner (14 July 2021). "Grapefruit Juice and Some Drugs Don't Mix". FDA (dalam bahasa Inggris). Diarsipkan dari asli tanggal 6 May 2019.
Oral H (14 September 2018). "Lurasidone is not associated with risk of QTc prolongation". Clinical Research in Practice: The Journal of Team Hippocrates. 4 (2). doi:10.22237/crp/1536278400. ISSN 2379-4550. S2CID 53322344. Diarsipkan dari versi aslinya tanggal 15 November 2022. Diakses tanggal 15 November 2022.
"Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study" (Press release). Dainippon Sumitomo Pharma. 26 August 2009. Diarsipkan dari asli tanggal 14 May 2015. Diakses tanggal 3 October 2016.
"Latuda: Prescribing Information". Psychotherapeutic Drugs. Diarsipkan dari asli tanggal 28 June 2011. Diakses tanggal 17 December 2010.
"Latuda". Drugs.com. Diarsipkan dari versi aslinya tanggal 5 April 2019. Diakses tanggal 17 December 2010.
"Latuda Prescribing Information" (PDF). Sunovion Pharmaceuticals. Diarsipkan (PDF) dari versi aslinya tanggal 12 July 2018. Diakses tanggal 25 March 2014.
Haddad PM, Dursun S, Deakin B, ed. (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. OUP Oxford. hlm. 207–216. ISBN 978-0-19-852748-0. Diarsipkan dari versi aslinya tanggal 10 January 2023. Diakses tanggal 8 May 2020.
Sacchetti E, Vita A, Siracusano A, Fleischhacker W (2013). Adherence to Antipsychotics in Schizophrenia. Springer Science & Business Media. hlm. 85. ISBN 978-88-470-2679-7. Diarsipkan dari versi aslinya tanggal 10 January 2023. Diakses tanggal 8 May 2020.
Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Diarsipkan dari versi aslinya tanggal 28 August 2021. Diakses tanggal 14 August 2017.
"(3aR,4S,7R,7aS)-2-[[(1R,2R)-2-[[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione". PubChem (dalam bahasa Inggris). U.S. National Library of Medicine. Diarsipkan dari versi aslinya tanggal 2 December 2022. Diakses tanggal 2 December 2022.
Lincoln J, Tripathi A (2011). "Lurasidone for Schizophrenia". Current Psychiatry. 10 (1): 67–70. Diarsipkan dari versi aslinya tanggal 3 October 2016. Diakses tanggal 2 October 2016.
"Lurasidone pharmacology review" (PDF). Center for Drug Evaluation and Research. 30 December 2009. Diarsipkan dari asli (PDF) tanggal 3 October 2016. Diakses tanggal 2 October 2016.
"European Medicines Agency Assessment report Latuda International non-proprietary name: LURASIDONE Procedure No. EMEA/H/C/002713/0000" (PDF). Diarsipkan (PDF) dari versi aslinya tanggal 14 November 2022. Diakses tanggal 14 November 2022.
Canadian Agency for Drugs and Technologies in Health (2014). "Summary of Pharmacoeconomic Submission". Lurasidone Hydrochloride (Latuda): Management of Manifestations of Schizophrenia. Canadian Agency for Drugs and Technologies in Health. Diarsipkan dari versi aslinya tanggal 28 August 2021. Diakses tanggal 30 April 2020 – via National Center for Biotechnology Information, U.S. National Library of Medicine.
"Drug Approval Package: Latuda (lurasidone hydrochloride) Tablets NDA #200603". U.S. Food and Drug Administration (FDA). 24 December 1999. Diarsipkan dari asli tanggal 25 February 2021. Diakses tanggal 12 May 2020.
"FDA approves Latuda to treat schizophrenia in adults" (Press release). U.S. Food and Drug Administration (FDA). 28 October 2010. Diarsipkan dari asli tanggal 30 October 2010. Diakses tanggal 29 October 2010.
"Lurasidone, 18.5mg, 37mg, 74mg film-coated tablets (Latuda) SMC No. (994/14)" (PDF). scottishmedicines.org.uk. Scottish Medicines Consortium. 2014. Diarsipkan dari asli (PDF) tanggal 8 March 2016. Diakses tanggal 7 March 2016.
"Summary Basis of Decision (SBD) for Latuda". hc-sc.gc.ca. Health Canada. 2012. Diarsipkan dari versi aslinya tanggal 27 June 2013. Diakses tanggal 19 June 2013.
"European Marketing Authorization for Latuda". takeda.com. Diarsipkan dari asli tanggal 26 December 2017. Diakses tanggal 25 November 2015.
"Lurasidone: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Diarsipkan dari asli tanggal 1 October 2020. Diakses tanggal 12 May 2020.

worldcat.org (Global: 5^th place; Indonesian: 7^th place)

search.worldcat.org

Oral H (14 September 2018). "Lurasidone is not associated with risk of QTc prolongation". Clinical Research in Practice: The Journal of Team Hippocrates. 4 (2). doi:10.22237/crp/1536278400. ISSN 2379-4550. S2CID 53322344. Diarsipkan dari versi aslinya tanggal 15 November 2022. Diakses tanggal 15 November 2022.

wsj.com (Global: 79^th place; Indonesian: 211^th place)

Hopkins JS (19 November 2019). "Generic-Drug Approvals Soar, But Patients Still Go Without". Wall Street Journal. Diarsipkan dari versi aslinya tanggal 27 April 2020. Diakses tanggal 30 April 2020.

Lurasidon (Indonesian Wikipedia)

archive.org (Global: 6th place; Indonesian: 2nd place)

books.google.com (Global: 3rd place; Indonesian: 6th place)

doi.org (Global: 2nd place; Indonesian: 4th place)

drugs.com (Global: 399th place; Indonesian: 480th place)

ds-pharma.com (Global: low place; Indonesian: low place)

europa.eu (Global: 68th place; Indonesian: 182nd place)

ema.europa.eu

excli.de (Global: low place; Indonesian: low place)

fda.gov (Global: 447th place; Indonesian: 792nd place)

accessdata.fda.gov

fda.gov

handle.net (Global: 102nd place; Indonesian: 411th place)

hdl.handle.net

hc-sc.gc.ca (Global: low place; Indonesian: 4,221st place)

in.gov.br (Global: 3,151st place; Indonesian: low place)

jiho.jp (Global: low place; Indonesian: low place)

pj.jiho.jp

kcl.ac.uk (Global: 3,833rd place; Indonesian: low place)

kclpure.kcl.ac.uk

latuda.com (Global: low place; Indonesian: low place)

mdedge.com (Global: low place; Indonesian: low place)

medicines.org.uk (Global: 3,823rd place; Indonesian: 9,839th place)

medlineplus.gov (Global: 1,581st place; Indonesian: 2,421st place)

medscape.com (Global: 719th place; Indonesian: 1,112th place)

mmm-online.com (Global: low place; Indonesian: low place)

nih.gov (Global: 4th place; Indonesian: 13th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

psychotherapeuticdrugs.com (Global: low place; Indonesian: low place)

rad-ar.or.jp (Global: low place; Indonesian: low place)

scottishmedicines.org.uk (Global: low place; Indonesian: low place)

semanticscholar.org (Global: 11th place; Indonesian: 330th place)

api.semanticscholar.org

sps.nhs.uk (Global: low place; Indonesian: low place)

sumitomo-pharma.com (Global: low place; Indonesian: low place)

takeda.com (Global: low place; Indonesian: low place)

tpi.takeda.com

tga.gov.au (Global: 3,984th place; Indonesian: 4,575th place)

ebs.tga.gov.au

tga.gov.au

unc.edu (Global: 1,538th place; Indonesian: 1,848th place)

pdsp.unc.edu

wayne.edu (Global: 8,028th place; Indonesian: low place)

digitalcommons.wayne.edu

web.archive.org (Global: 1st place; Indonesian: 1st place)

worldcat.org (Global: 5th place; Indonesian: 7th place)

search.worldcat.org

wsj.com (Global: 79th place; Indonesian: 211th place)

archive.org (Global: 6^th place; Indonesian: 2^nd place)

books.google.com (Global: 3^rd place; Indonesian: 6^th place)

doi.org (Global: 2^nd place; Indonesian: 4^th place)

drugs.com (Global: 399^th place; Indonesian: 480^th place)

europa.eu (Global: 68^th place; Indonesian: 182^nd place)

fda.gov (Global: 447^th place; Indonesian: 792^nd place)

handle.net (Global: 102^nd place; Indonesian: 411^th place)

hc-sc.gc.ca (Global: low place; Indonesian: 4,221^st place)

in.gov.br (Global: 3,151^st place; Indonesian: low place)

kcl.ac.uk (Global: 3,833^rd place; Indonesian: low place)

medicines.org.uk (Global: 3,823^rd place; Indonesian: 9,839^th place)

medlineplus.gov (Global: 1,581^st place; Indonesian: 2,421^st place)

medscape.com (Global: 719^th place; Indonesian: 1,112^th place)

nih.gov (Global: 4^th place; Indonesian: 13^th place)

semanticscholar.org (Global: 11^th place; Indonesian: 330^th place)

tga.gov.au (Global: 3,984^th place; Indonesian: 4,575^th place)

unc.edu (Global: 1,538^th place; Indonesian: 1,848^th place)

wayne.edu (Global: 8,028^th place; Indonesian: low place)

web.archive.org (Global: 1^st place; Indonesian: 1^st place)

worldcat.org (Global: 5^th place; Indonesian: 7^th place)

wsj.com (Global: 79^th place; Indonesian: 211^th place)